Walter K Kraft1, Susan C Adeniyi-Jones1, Inna Chervoneva1, Jay S Greenspan1, Diane Abatemarco1, Karol Kaltenbach1, Michelle E Ehrlich1. 1. From Sidney Kimmel Medical College, Thomas Jefferson University (W.K.K., S.C.A.-J., I.C., J.S.G., D.A., K.K.), and Nemours duPont Pediatrics, Thomas Jefferson University Hospital (S.C.A.-J., J.S.G.) - both in Philadelphia; and the Departments of Neurology, Pediatrics, and Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York (M.E.E.).
Abstract
BACKGROUND: Current pharmacologic treatment of the neonatal abstinence syndrome with morphine is associated with a lengthy duration of therapy and hospitalization. Buprenorphine may be more effective than morphine for this indication. METHODS: In this single-site, double-blind, double-dummy clinical trial, we randomly assigned 63 term infants (≥37 weeks of gestation) who had been exposed to opioids in utero and who had signs of the neonatal abstinence syndrome to receive eithersublingual buprenorphine or oral morphine. Infants with symptoms that were not controlled with the maximum dose of opioid were treated with adjunctive phenobarbital. The primary end point was the duration of treatment for symptoms of neonatal opioid withdrawal. Secondary clinical end points were the length of hospital stay, the percentage of infants who required supplemental treatment with phenobarbital, and safety. RESULTS: The median duration of treatment was significantly shorter with buprenorphine than with morphine (15 days vs. 28 days), as was the median length of hospital stay (21 days vs. 33 days) (P<0.001 for both comparisons). Adjunctive phenobarbital was administered in 5 of 33 infants (15%) in the buprenorphine group and in 7 of 30 infants (23%) in the morphine group (P=0.36). Rates of adverse events were similar in the two groups. CONCLUSIONS: Among infants with the neonatal abstinence syndrome, treatment with sublingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital stay than treatment with oral morphine, with similar rates of adverse events. (Funded by the National Institute on Drug Abuse; BBORN ClinicalTrials.gov number, NCT01452789 .).
RCT Entities:
BACKGROUND: Current pharmacologic treatment of the neonatal abstinence syndrome with morphine is associated with a lengthy duration of therapy and hospitalization. Buprenorphine may be more effective than morphine for this indication. METHODS: In this single-site, double-blind, double-dummy clinical trial, we randomly assigned 63 term infants (≥37 weeks of gestation) who had been exposed to opioids in utero and who had signs of the neonatal abstinence syndrome to receive either sublingual buprenorphine or oral morphine. Infants with symptoms that were not controlled with the maximum dose of opioid were treated with adjunctive phenobarbital. The primary end point was the duration of treatment for symptoms of neonatal opioid withdrawal. Secondary clinical end points were the length of hospital stay, the percentage of infants who required supplemental treatment with phenobarbital, and safety. RESULTS: The median duration of treatment was significantly shorter with buprenorphine than with morphine (15 days vs. 28 days), as was the median length of hospital stay (21 days vs. 33 days) (P<0.001 for both comparisons). Adjunctive phenobarbital was administered in 5 of 33 infants (15%) in the buprenorphine group and in 7 of 30 infants (23%) in the morphine group (P=0.36). Rates of adverse events were similar in the two groups. CONCLUSIONS: Among infants with the neonatal abstinence syndrome, treatment with sublingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital stay than treatment with oral morphine, with similar rates of adverse events. (Funded by the National Institute on Drug Abuse; BBORN ClinicalTrials.gov number, NCT01452789 .).
Authors: Neil S Seligman; Nicole Salva; Edward J Hayes; Kevin C Dysart; Edward C Pequignot; Jason K Baxter Journal: Am J Obstet Gynecol Date: 2008-10 Impact factor: 8.661
Authors: Stephen W Patrick; Robert E Schumacher; Jeffrey D Horbar; Madge E Buus-Frank; Erika M Edwards; Kate A Morrow; Karla R Ferrelli; Alan P Picarillo; Munish Gupta; Roger F Soll Journal: Pediatrics Date: 2016-04-15 Impact factor: 7.124
Authors: Ellena A Anagnostis; Rania E Sadaka; Linda A Sailor; David E Moody; Kevin C Dysart; Walter K Kraft Journal: J Pediatr Pharmacol Ther Date: 2011-10
Authors: Walter K Kraft; Eric Gibson; Kevin Dysart; Vidula S Damle; Jennifer L Larusso; Jay S Greenspan; David E Moody; Karol Kaltenbach; Michelle E Ehrlich Journal: Pediatrics Date: 2008-08-11 Impact factor: 7.124
Authors: Jason N Moore; Marc R Gastonguay; Chee M Ng; Susan C Adeniyi-Jones; David E Moody; Wenfang B Fang; Michelle E Ehrlich; Walter K Kraft Journal: Clin Pharmacol Ther Date: 2018-04-28 Impact factor: 6.875
Authors: Tyler N A Winkelman; Nicole Villapiano; Katy B Kozhimannil; Matthew M Davis; Stephen W Patrick Journal: Pediatrics Date: 2018-04 Impact factor: 7.124
Authors: Jonathan M Davis; Jeffrey Shenberger; Norma Terrin; Janis L Breeze; Mark Hudak; Elisha M Wachman; Peter Marro; Erica L Oliveira; Karen Harvey-Wilkes; Adam Czynski; Barbara Engelhardt; Karen D'Apolito; Debra Bogen; Barry Lester Journal: JAMA Pediatr Date: 2018-08-01 Impact factor: 16.193